Publicaciones en colaboración con investigadores/as de University of the Witwatersrand (63)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age

    HIV Medicine, Vol. 24, Núm. 1, pp. 27-36

  3. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  4. Effective early antiretroviral therapy in perinatal-HIV infection reduces subsequent plasma inflammatory profile

    Pediatric Research, Vol. 94, Núm. 5, pp. 1667-1674

  5. Genomic investigations of unexplained acute hepatitis in children

    Nature, Vol. 617, Núm. 7961, pp. 564-573

  6. Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial

    eClinicalMedicine, Vol. 60

2022

  1. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

    The Lancet HIV, Vol. 9, Núm. 9, pp. e627-e637

  2. Identifying the research, advocacy, policy and implementation needs for the prevention and management of respiratory syncytial virus lower respiratory tract infection in low- and middle-income countries

    Frontiers in Pediatrics, Vol. 10

  3. Machine learning outperformed logistic regression classification even with limit sample size: A model to predict pediatric HIV mortality and clinical progression to AIDS

    PloS one, Vol. 17, Núm. 10, pp. e0276116

  4. Multiplex PCR Detection of Respiratory Tract Infections in SARS-CoV-2-Negative Patients Admitted to the Emergency Department: an International Multicenter Study during the COVID-19 Pandemic

    Microbiology Spectrum, Vol. 10, Núm. 5

  5. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

    The Lancet HIV, Vol. 9, Núm. 9, pp. e638-e648

  6. Optimizing the World Health Organization algorithm for HIV vertical transmission risk assessment by adding maternal self-reported antiretroviral therapy adherence

    BMC public health, Vol. 22, Núm. 1, pp. 1312

  7. Perspectives of patients, family members, health professionals and the public on the impact of COVID-19 on mental health

    Journal of Mental Health, Vol. 31, Núm. 4, pp. 524-533

2021

  1. Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial

    Infectious Diseases and Therapy, Vol. 10, Núm. 2, pp. 775-788

  2. Core Outcome Measures for Trials in People with Coronavirus Disease 2019: Respiratory Failure, Multiorgan Failure, Shortness of Breath, and Recovery

    Critical Care Medicine, Vol. 49, Núm. 3, pp. 503-516

  3. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

    New England Journal of Medicine, Vol. 385, Núm. 27, pp. 2531-2543

  4. Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight

    eLife, Vol. 10

  5. Repurposed antiviral drugs for COVID-19 — InteriM WHO solidarity trial results

    New England Journal of Medicine, Vol. 384, Núm. 6, pp. 497-511

  6. Understanding the host in the management of pneumonia: An official American thoracic society workshop report

    Annals of the American Thoracic Society, Vol. 18, Núm. 7, pp. 1087-1097

2020

  1. Core Outcomes Set for Trials in People With Coronavirus Disease 2019

    Critical Care Medicine, Vol. 48, Núm. 11, pp. 1622-1635